Venmax Drugs and Pharmaceuticals Q4 FY26 Results: Announced May 14 2026 Pharmaceuticals
- May 15, 2026
- Posted by: Neeraj Pandey
- Category: News
Venmax Drugs and Pharmaceuticals Q4 FY26 Results: Announced May 14 2026 Pharmaceuticals company results were announced on May 14, 2026, at the company’s board meeting. Q4 FY26 PAT approximately Rs 1 crore on revenue approximately Rs 15 crore. Generic pharmaceutical manufacturer. Results filed with BSE on May 14, 2026. Investors tracking the company will find complete financial data, analysis, and FY27 outlook in this article.
Click Here – Get Free Investment Predictions
Venmax Drugs and Pharmaceuticals Q4 FY26 Key Financial Highlights
| Metric | Q4 FY26 | Comparison |
|---|---|---|
| PAT (Net Profit) | Rs 1 crore | Q4 FY26 |
| Revenue from Operations | Rs 15 crore | Q4 FY26 |
| Ticker | VENMAX | Sector: Pharmaceuticals |
Screen the best stocks on the Univest Screener.
Venmax Drugs and Pharmaceuticals Performance Analysis
The company results reflect the company’s operational performance during the January to March 2026 quarter. the company results announced May 14, 2026. The company manufactures pharmaceutical formulations for domestic markets. Investors and analysts monitoring the company results will focus on FY27 revenue guidance, margin trajectory, and management commentary on business outlook.
The company performance positions the company for FY27. Track the company analyst ratings and live stock price on the Univest Screener for real-time investment insights.
Venmax Drugs and Pharmaceuticals FY27 Outlook
Post Venmax, investor focus for FY27 will be on revenue growth momentum, margin expansion, new order wins, and sector-specific tailwinds in the Pharmaceuticals space. The Venmax results demonstrate the company’s execution capabilities. Track Venmax updates on the Univest Screener for analyst views and FY27 earnings estimates.
Download the Univest iOS App or the Univest Android App to track live price and Q4 FY26 earnings updates.
Frequently Asked Questions on Venmax Drugs and Pharmaceuticals Q4 FY26 Results
What is Venmax Drugs and Pharmaceuticals Q4 FY26 PAT?
Ans. Venmax Drugs and Pharmaceuticals Q4 FY26 PAT of Rs 1 crore (results declared May 14, 2026). Q4 FY26 PAT approximately Rs 1 crore on revenue approximately Rs 15 crore. Generic pharmaceutical manufacturer. Results filed with BSE on May 14, 2026.
When did Venmax Drugs and Pharmaceuticals announce Q4 FY26 results?
Ans. the company results were announced on May 14, 2026, at the company’s board meeting and filed with BSE and NSE.
What is the FY27 outlook for Venmax Drugs and Pharmaceuticals?
Ans. Post the company results, investors will track FY27 guidance and growth strategies in the Pharmaceuticals sector. Track live updates on the Univest Screener.
Where can I track Venmax Drugs and Pharmaceuticals Q4 FY26 live data?
Ans. Track the company live stock price, analyst ratings, and earnings updates on the Univest Screener for real-time investment data.
Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Consult a SEBI-registered advisor before making any investment decision.
